Page last updated: 2024-09-04

atazanavir and lapatinib

atazanavir has been researched along with lapatinib in 2 studies

Compound Research Comparison

Studies
(atazanavir)
Trials
(atazanavir)
Recent Studies (post-2010)
(atazanavir)
Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010) (lapatinib)
751371,9193051,442

Protein Interaction Comparison

ProteinTaxonomyatazanavir (IC50)lapatinib (IC50)
Bile salt export pumpHomo sapiens (human)7.375
Epidermal growth factor receptorHomo sapiens (human)0.0827
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0537
Platelet-derived growth factor receptor betaHomo sapiens (human)8.5
D(1A) dopamine receptorSus scrofa (pig)0.06
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.1659
Alpha-1A adrenergic receptor Sus scrofa (pig)0.06
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.2

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1

Reviews

2 review(s) available for atazanavir and lapatinib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022